The varied nature of asthma is not adequately captured by current recommendations; a more comprehensive molecular classification is required. Metabolomics is a fresh and intriguing method for determining asthma endotypes or subgroups defined by functional/pathobiological causes. Validate metabolomic-driven asthma endotypes and investigate their underlying biology. Untargeted metabolomic profiling, Similarity Network Fusion, and spectral clustering were employed in the Genetics of Asthma in Costa Rica Study (GACRS) to identify Metabo-endotypes of asthma and investigate the differences in asthma-relevant phenotypes across these Metabo-endotypes.
The CAMP (Childhood Asthma Management Program) was used to recreate the Metabo-endotypes and assess clinical differences. The meta-analysis of GACRS and CAMP data revealed metabolomic determinants of Metabo-endotype membership. Pre-bronchodilator (p-ANOVA=8.3×10-5) and post-bronchodilator (p-ANOVA=1.8×10-5) forced expiratory volume/forced vital capacity (FEV1/FVC) forced expiratory book/forced necessary capacity (FEV1/FVC) forced expiratory volume/forced necessary capacity (FEV1/FVC) forced expiratory volume/forced vital capacity (FEV1/FVC) forced expiratory book/forced necessary power ( These distinctions were confirmed in CAMP’s recapitulated Metabo-endotypes. The most important drivers of Metabo-endotype membership were cholesterol esters, triglycerides, and fatty acids. The findings show that pulmonary surfactant homeostasis disruption may contribute to asthma severity.
They developed and verified clinically significant endotypes using metabolomic data. They investigated drivers of these Metabo-endotypes to learn more about their pathophysiology.
Reference:www.atsjournals.org/doi/abs/10.1164/rccm.202105-1268OC
